Table 3.
Comparisons of numbers of >2-fold up- regulated and >2-fold down-regulated proteins expressed in urinary exosomes from ADPKD patients treated with Tolvaptan for 5 years: effects of disease progression and therapeutic efficacy.
| eGFR at onset of treatment | Progression rate/year | Response to Tolvaptan | Up-regulated Proteins | Down-regulated Proteins |
|---|---|---|---|---|
| 58ml/min | 3.3ml/min | Good | 464 | 14 |
| 32ml/min | 5ml/min | Good | 107 | 5 |
| 52ml/min | 5ml/min | Poor | 58 | 2175 |
| 30ml/min | 7.5ml/min | Poor | 49 | 346 |
| 75ml/min | 5ml/min | Uncertain | 38 | 336 |
| 38ml/min | 6.25ml/min | Uncertain | 4 | 767 |